Rigel Pharmaceuticals (RIGL)
Turbulence: High Sector-strength: 84th pctile elevated vs peers
Rigel Pharmaceuticals sits in the High turbulence band, around the 84th percentile of Health Care on balance-sheet strength. The lens reads it as elevated vs peers. The underlying figures, all from public filings:
| Revenue (TTM) | $294M |
| Net income (TTM) | $367M |
| Operating margin | 42.6% |
| FCF margin | 25.6% |
| Altman Z | n/a |
| Piotroski F | 7 |
| Beneish M | n/a |
| Interest coverage | 17.14 |
See the full deep-dive in the app →
Figures from public filings (EDGAR). Descriptive, not advice. No targets, no buy or sell. Price and valuation live in the app.
Get the weekly read by email
The Filter covers the macro backdrop and where balance-sheet strength matters, in the same language as the page above. Descriptive only.
No spam, and the list is never sold or shared. Unsubscribe from any issue.